Cladribine
- Generic Name
- Cladribine
- Brand Names
- Litak, Mavenclad
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12ClN5O3
- CAS Number
- 4291-63-8
- Unique Ingredient Identifier
- 47M74X9YT5
- Background
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
- Indication
For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Cutaneous T-Cell Lymphoma (CTCL), Hairy Cell Leukemia (HCL), Non-Hodgkin's Lymphomas, Active confirmed by clinical features, confirmed by imaging features relapsing multiple sclerosis (MS)
- Associated Therapies
- -
Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL
- Conditions
- Leukemia
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2012-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 43
- Registration Number
- NCT00072007
- Locations
- 🇨🇭
Hopital des Cadolles, Neuchatel, Neuchatel, Switzerland
🇨🇭Spitaeler Chur AG, Chur, Switzerland
🇨🇭Kantonsspital - St. Gallen, St. Gallen, Switzerland
Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 30
- Registration Number
- NCT00053027
Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 120
- Registration Number
- NCT00003178
- Locations
- 🇺🇸
Simmons Cancer Center - Dallas, Dallas, Texas, United States
🇺🇸Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-04-24
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 80
- Registration Number
- NCT00003174
- Locations
- 🇺🇸
Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis
- Conditions
- Cholangitis, Sclerosing
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 5
- Registration Number
- NCT00004762
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.